WO2020071464A1 - α GEL HAVING GLYCYRRHETINIC ACID DERIVATIVE AS STRUCTURAL COMPONENT, COMPOSITION CONTAINING α GEL, METHOD FOR PRODUCING α GEL, AND COSMETIC CONTAINING α GEL - Google Patents

α GEL HAVING GLYCYRRHETINIC ACID DERIVATIVE AS STRUCTURAL COMPONENT, COMPOSITION CONTAINING α GEL, METHOD FOR PRODUCING α GEL, AND COSMETIC CONTAINING α GEL

Info

Publication number
WO2020071464A1
WO2020071464A1 PCT/JP2019/039037 JP2019039037W WO2020071464A1 WO 2020071464 A1 WO2020071464 A1 WO 2020071464A1 JP 2019039037 W JP2019039037 W JP 2019039037W WO 2020071464 A1 WO2020071464 A1 WO 2020071464A1
Authority
WO
WIPO (PCT)
Prior art keywords
gel
mass
component
composition
acid derivative
Prior art date
Application number
PCT/JP2019/039037
Other languages
French (fr)
Japanese (ja)
Inventor
良 池田
Original Assignee
丸善製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丸善製薬株式会社 filed Critical 丸善製薬株式会社
Priority to KR1020217010922A priority Critical patent/KR20210071996A/en
Priority to JP2020550525A priority patent/JPWO2020071464A1/en
Priority to CN201980064673.4A priority patent/CN112888422A/en
Publication of WO2020071464A1 publication Critical patent/WO2020071464A1/en
Priority to JP2023195681A priority patent/JP2024003242A/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to an ⁇ -gel having a glycyrrhetinic acid derivative as a constituent, a composition containing the ⁇ -gel, a method for producing the ⁇ -gel, a transdermal absorption enhancer of the glycyrrhetinic acid derivative, and a cosmetic containing the ⁇ -gel.
  • Glycyrrhetinic acid derivatives are known as active ingredients having anti-inflammatory pharmacological activity. In order to exhibit its excellent pharmacological activity, it is important that it is absorbed transdermally into the skin, scalp and the like.
  • the dosage form is limited to a formulation capable of highly blending an oil component such as a cream, and can be incorporated into other dosage forms. Technology was desired.
  • the present invention has been made in view of the above circumstances, and by using an ⁇ -gel having a glycyrrhetinic acid derivative as a constituent component, it is possible to mix the glycyrrhetinic acid derivative in a dosage form in which water is highly blended, and further, the glycyrrhetinic acid derivative It is an object of the present invention to provide a technique for promoting percutaneous absorption of a drug.
  • the present inventors have conducted intensive studies in order to achieve the above object, and as a result, by adopting a specific configuration, an ⁇ -gel containing a glycyrrhetinic acid derivative has been obtained, and it has been found that the above problem can be solved. It is a thing.
  • the present invention provides the following inventions.
  • A a glycyrrhetinic acid derivative
  • B at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms
  • C one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants
  • ⁇ -gel having (D) dipropylene glycol and (E) water as constituent components.
  • Method. A transdermal absorption enhancer of a glycyrrhetinic acid derivative, comprising the ⁇ -gel of 4.1 as an active ingredient.
  • a cosmetic comprising the ⁇ -gel of 5.1.
  • an ⁇ -gel capable of blending a glycyrrhetinic acid derivative into a dosage form in which water is highly blended and further promoting percutaneous absorption of the glycyrrhetinic acid derivative. Further, it is possible to provide a composition containing an ⁇ -gel, a method for producing the ⁇ -gel, a transdermal absorption enhancer of a glycyrrhetinic acid derivative, and a cosmetic containing the ⁇ -gel.
  • Example 1-1 shows the appearance photographs of Example 1-1 and Comparative Example 1-1.
  • 10 shows the results of DSC of Example 1-1.
  • 6 shows the results of X-ray scattering analysis of Example 1-1.
  • the ⁇ -gel in the present invention includes (A) a glycyrrhetinic acid derivative, (B) one or more selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms, (C) an anionic surfactant, and a cationic interface.
  • An association body comprising a lamellar bimolecular film formed in the presence of (D) dipropylene glycol and (E) water with at least one selected from a surfactant, a nonionic surfactant and an amphoteric surfactant Say.
  • (B) the alkyl chain of the aliphatic alcohol or fatty acid, (A) the glycyrrhetinic acid derivative and (C) the alkyl chain of the surfactant form a hexagonal crystal.
  • this hexagonal structure has a laminated structure of a bilayer film, and forms an ⁇ -type hydrated crystal.
  • the ⁇ -type hydrated crystal retains a large amount of water and (D) dipropylene glycol between the layers of the bilayer structure, and exhibits a gel state by retaining moisture by the network structure of the bimolecular film.
  • glycyrrhetinic acid derivative examples include stearyl glycyrrhetinate, glycyrrhetinyl stearate, and the like, and these can be used alone or in an appropriate combination of two or more. Each of these has a hydrophilic group and a hydrophobic group.
  • the component (B) of the present invention is at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms, and can be used alone or in an appropriate combination of two or more. These aliphatic groups are preferably straight-chain. By selecting such specific components, an ⁇ -gel structure can be formed.
  • the aliphatic alcohol having 14 to 18 carbon atoms include myristyl alcohol (1-tetradecanol), cetyl alcohol (1-hexadecanol), cetostearyl alcohol, stearyl alcohol (octadecyl alcohol), and oleyl alcohol. Among them, cetyl alcohol is preferred.
  • the fatty acid having 14 to 18 carbon atoms include myristic acid, palmitic acid, stearic acid, and oleic acid.
  • the component (C) of the present invention is at least one selected from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants, and one type alone or two or more types as appropriate. They can be used in combination.
  • the anionic surfactant preferably has a trans-type hydrophilic alkyl group, and may be used alone or in combination of two or more.
  • N-acyl-N-methyltaurine salts such as alkyl sulfonates, alkyl sulfates, acylated amino acid salts, polyoxyethylene alkyl ether sulfates, alkylbenzene sulfonates, N-stearoyl-N-methyltaurine salts, ⁇ -olefin sulfonate, higher fatty acid ester sulfonate, alkyl ether acetate, polyoxyethylene alkyl ether acetate, fatty acid soap such as sodium stearate, alkyl phosphate ester salt, N-stearoyl glutamate, N-lauroyl Glutamates, N-palmitoyl glutamates, N-lauroyl glutamates, acyl glutamates such as N-palmitoyl glutamate,
  • Salts include alkali metals, alkaline earth metals, ammonium, alkanolamines, basic amino acids and the like. Among them, N-acyl-N-methyltaurate, N-stearoylglutamate, stearate, stearoyl lactate and the like are preferable.
  • the cationic surfactant preferably has a trans-type in which the alkyl chain of the hydrophilic group is trans-type, and may be used alone or in combination of two or more. Specific examples include quaternary ammonium salts such as alkyltrimethylammonium salts, dialkyldimethylammonium salts and alkylammonium salts, benzalkonium salts, pyridinium salts, amidoamine compounds and the like.
  • Examples of the counter ion of the cationic surfactant include halogen ions such as chloride ion and bromide ion, methyl sulfate ion (CH 3 OSO 3 ⁇ ), and ethyl sulfate ion (CH 3 CH 2 OSO 3 ⁇ ).
  • halogen ions such as chloride ion and bromide ion, methyl sulfate ion (CH 3 OSO 3 ⁇ ), and ethyl sulfate ion (CH 3 CH 2 OSO 3 ⁇ ).
  • halogen ions such as chloride ion and bromide ion, methyl sulfate ion (CH 3 OSO 3 ⁇ ), and ethyl sulfate ion (CH 3 CH 2 OSO 3 ⁇ ).
  • nonionic surfactant those having a trans-alkyl chain of a hydrophilic group are preferable, and one type can be used alone or two or more types can be used in appropriate combination.
  • polyoxyethylene glyceryl monostearate polyoxyethylene stearyl ether, polyethylene glycol monostearate, and polyoxyethylene cetyl ether.
  • PEG-40 glyceryl stearate, ⁇ -octadecyl ⁇ -hydroxypoly (oxyethylene), PEG-32 stearate, and Ceteth-30 are preferable.
  • amphoteric surfactant those having a trans-alkyl chain of a hydrophilic group are preferable, and one type can be used alone or two or more types can be used in appropriate combination.
  • alkyl betaine-based activators such as betaine alkyldimethylaminoacetate, amidobetaine-based activators such as alkylamidopropylbetaine, sulfobetaine-based activators, hydroxysulfobetaine-based activators, amide sulfobetaine-based activators, Examples include phosphobetaine-based activators, imidazolinium betaine-based activators, aminopropionic acid-based activators, amino acid-based activators, and amine oxides. Among them, dimethyloctadecylamine N-oxide, stearyldimethylamine oxide and the like are preferable.
  • anionic surfactants are preferable, and N-acyl-N-methyltaurate and N-stearoylglutamate are more preferable.
  • the component (D) of the present invention is dipropylene glycol.
  • dipropylene glycol By using dipropylene glycol, an ⁇ -gel containing a glycyrrhetinic acid derivative can be formed.
  • the component (E) of the present invention is water, and is not particularly limited as long as it is water such as purified water.
  • Whether or not an ⁇ -gel is formed can be determined by the appearance of a uniform one-phase state, preferably a thickened uniform one-phase state, which is characteristic of the ⁇ -gel, and by a single differential scanning calorimetry (DSC). By confirming the phase transition temperature, it is confirmed that an ⁇ -gel was formed. Furthermore, it can be confirmed by X-ray scattering analysis.
  • composition containing ⁇ -gel The present invention provides (A) a glycyrrhetinic acid derivative: 0.05 to 1% by mass, (B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms, (C) one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: total amount of component (B) and component (C) 0.5 to 20 mass %, A composition comprising (D) 2.5 to 40% by mass of dipropylene glycol and (E) water and comprising an ⁇ -gel is provided. This composition contains the above-mentioned ⁇ -gel. From the viewpoint of ⁇ -gel formation, the content of each component is as follows. In addition, what constitutes (alpha) gel is also contained in the following content.
  • the content of the component (A) is 0.05 to 1% by mass in the composition, and preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is 0.5 to 20% by mass, preferably 0.5 to 12% by mass in the composition.
  • the mass ratio of (B) :( C) varies depending on the type of surfactant, but is preferably 0.5: 1 to 5: 1, more preferably 1: 1 to 4: 1, and 1.3: 1. 33: 1 is most preferred.
  • the content of the component (B) is preferably 0.3 to 16.0% by mass in the composition, and the content of the component (C) is preferably 0.2 to 8.0% by mass in the composition.
  • the content of the component (D) is 2.5 to 40% by mass in the composition, and preferably 2.5 to 20% by mass.
  • the compounding ratio of the component (A): the sum of the components (B) and (C): the component (D) is preferably from 0.05 to 1: 0.5 to 20: 2.5 to 40.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably from 0.5 to 20% by mass, more preferably from 0.5 to 12% by mass in the composition.
  • the mass ratio of (B) :( C) is preferably from 1: 1 to 5: 1.
  • the content of the component (D) in the composition is preferably 2.5 to 40% by mass, more preferably 2.5 to 20% by mass, and still more preferably 2.5 to 10% by mass.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition.
  • the mass ratio of (B) :( C) is preferably from 1: 1 to 3: 1.
  • the content of the component (D) is preferably 2.5 to 40% by mass, more preferably 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition.
  • the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition.
  • the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition.
  • the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is 2.5 to 40% by mass in the composition, and more preferably 2.5 to 30% by mass.
  • the content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
  • the total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition.
  • the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
  • the content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
  • the content of the component (E) is preferably 58.5 to 96.95% by mass, more preferably 78.5 to 96.0% by mass in the composition. With the constitution of the present invention, a composition having such a high water content can be obtained.
  • Optional component various components that can be added to cosmetics, hair restorer, pharmaceuticals, quasi-drugs and the like can be added in appropriate amounts as long as the effects of the present invention are not impaired.
  • oils such as silicone oils, ester oils and vegetable oils, silicone powders, polymer compounds, solvents such as ethanol, lower alcohols (2 to 5 carbon atoms), and higher alcohols (6 to 5 carbon atoms).
  • Functional ingredients such as alcohols, thickeners, powders, whitening agents, anti-aging agents, humectants, preservatives, antibacterial agents, enzymes, plant extracts, etc., as well as fragrances, pigments, pH adjusters, etc. Is mentioned. Each of these can be used alone or in combination of two or more.
  • the viscosity at 25 ° C. of the composition containing the ⁇ -gel is preferably from 1,000 to 10,000 mPa ⁇ s.
  • the viscosity is measured by a B-type viscometer, for example, manufactured by BROOKFILD.
  • Method for producing ⁇ -gel or composition containing ⁇ -gel ⁇ -gel or a composition comprising ⁇ -gel,
  • A glycyrrhetinic acid derivative: 0.05 to 1% by mass
  • B at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms
  • C one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: the total amount of components (B) and (C) is at least 0.5% by mass.
  • It can be manufactured by including a step of uniformly mixing (D) 2.5 to 40% by mass of dipropylene glycol and water (E) after heating and dissolving, and cooling to room temperature.
  • the heating temperature is not particularly limited, but is preferably from 70 to 90 ° C.
  • Mixing is not particularly limited, and mixing can be performed using a known mixing device.
  • the mixing speed, mixing device, and mixing time are not particularly limited as long as a one-phase thickened substance is formed, but the mixing speed is preferably 150 rpm or more, more preferably 200 rpm or more.
  • the upper limit is not particularly limited, but can be appropriately selected within a range of 10,000 rpm or less by a mixing device or the like.
  • the mixing time is preferably 1 minute or more, more preferably 2 to 10 minutes. Then, it cools to room temperature (about 20 degreeC).
  • the gel structure of the present invention has an excellent effect of promoting percutaneous absorption of the glycyrrhetinic acid derivative (A). Therefore, there is provided (A) a transdermal absorption enhancer of a glycyrrhetinic acid derivative containing the ⁇ -gel as an active ingredient. Suitable components and contents are as described above.
  • the ⁇ -gel can be blended with cosmetics, and a cosmetic containing the ⁇ -gel can be provided.
  • This cosmetic may use the composition containing the ⁇ -gel as a cosmetic. Furthermore, it can be blended with hair restorers, pharmaceuticals, quasi-drugs, and the like.
  • the amount of the ⁇ -gel in the cosmetic is not particularly limited, and is appropriately selected within the range of 5 to 100% by mass.
  • the cosmetic is not particularly limited, and examples thereof include skin cosmetics and hair cosmetics.
  • skin cosmetics include foundations (including all solids and liquids), makeup bases, shadows, lipsticks, lip balms, cheeks, eyebrow, mascara, eye lines, sunscreens, and other makeup cosmetics, lotions, emulsions, and creams , Serum, eye cream, pack and the like.
  • Other examples include antiperspirants.
  • Hair cosmetics include shampoos, rinses, treatments and the like.
  • Examples and Comparative Examples The following composition was heated at 90 ° C., mixed, mixed for 10 minutes using a shaker, and then cooled to room temperature (20 ° C.) to obtain a composition. With respect to the obtained composition, formation of an ⁇ -gel was confirmed from the appearance of the composition and the result of DSC measurement based on the following criteria.
  • the viscosity was measured with a B-type viscometer (manufactured by BROOKFILD).
  • BROOKFILD BROOKFILD
  • ⁇ -gel The composition had the appearance of a single-phase state in which the viscosity was increased, and a single phase transition temperature could be confirmed by DSC.
  • ⁇ The composition had a uniform one-phase appearance, and a single phase transition temperature could be confirmed by DSC.
  • ⁇ The composition was confirmed to have two phases or crystals. ⁇ and ⁇ indicate that a gel was formed.
  • FIG. 1 shows external appearance photographs of Example 1-1 and Comparative Example 1-1.
  • FIG. 2 shows the result of DSC of Example 1-1.
  • FIG. 3 shows the result of X-ray scattering analysis of Example 1-1. Structural analysis also confirmed that an ⁇ -gel was formed.
  • HPLC high performance liquid chromatography
  • Transdermal absorption of stearyl glycyrrhetinate was promoted by using an ⁇ -gel having stearyl glycyrrhetinate as a component.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

Provided is a technique for forming an α gel having, as structural components: (A) a glycyrrhetinic acid derivative; (B) one or more selected from C14-18 aliphatic alcohols and fatty acids; (C) one or more selected from anionic surfactants, cationic surfactants, non-ionic surfactants, and amphoteric surfactants; (D) dipropylene glycol; and (E) water, thereby enabling a glycyrrhetinic acid derivative to be added to a dosage form that has a high water content and promoting the transdermal absorption of a glycyrrhetinic acid derivative.

Description

グリチルレチン酸誘導体を構成成分とするαゲル、αゲルを含む組成物、αゲルの製造方法、αゲルを含む化粧料Α-Gel Containing Glycyrrhetinic Acid Derivative, Composition Containing α-Gel, Method for Producing α-Gel, Cosmetic Containing α-Gel
　本発明は、グリチルレチン酸誘導体を構成成分として有するαゲル、αゲルを含む組成物、αゲルの製造方法、グリチルレチン酸誘導体の経皮吸収促進剤、及びαゲルを含む化粧料に関するものである。 The present invention relates to an α-gel having a glycyrrhetinic acid derivative as a constituent, a composition containing the α-gel, a method for producing the α-gel, a transdermal absorption enhancer of the glycyrrhetinic acid derivative, and a cosmetic containing the α-gel.
　グリチルレチン酸誘導体は、抗炎症作用の薬理活性を有する有効成分として知られている。その優れた薬理活性を発揮するためには、皮膚、頭皮等に経皮吸収されることが重要である。 Glycyrrhetinic acid derivatives are known as active ingredients having anti-inflammatory pharmacological activity. In order to exhibit its excellent pharmacological activity, it is important that it is absorbed transdermally into the skin, scalp and the like.
　有効成分の経皮吸収を促進させる技術としては、温度２０℃における表面張力が２９．５ｍＮ／ｍ以下である炭化水素油との組み合わせ（特許第５９９７５４６号公報）が提案されているが、さらに優れた効果が望まれていた。 As a technique for promoting percutaneous absorption of an active ingredient, a combination with a hydrocarbon oil having a surface tension of 29.5 mN / m or less at a temperature of 20 ° C. (Japanese Patent No. 59997546) has been proposed, but it is more excellent. Effect was desired.
　また、グリチルレチン酸誘導体は油溶性成分であるため、化粧料等の外用剤へ配合する場合は、剤型がクリーム等の油分が高配合できる処方に限定されており、その他の剤型へ配合できる技術が望まれていた。 In addition, since the glycyrrhetinic acid derivative is an oil-soluble component, when it is incorporated into an external preparation such as a cosmetic, the dosage form is limited to a formulation capable of highly blending an oil component such as a cream, and can be incorporated into other dosage forms. Technology was desired.
特許第５９９７５４６号公報Japanese Patent No. 59997546
　本発明は上記事情に鑑みなされたもので、グリチルレチン酸誘導体を構成成分として有するαゲルとすることで、水が高配合される剤型へのグリチルレチン酸誘導体の配合を可能とし、さらにグリチルレチン酸誘導体の経皮吸収を促進させる技術を提供することを目的とする。 The present invention has been made in view of the above circumstances, and by using an α-gel having a glycyrrhetinic acid derivative as a constituent component, it is possible to mix the glycyrrhetinic acid derivative in a dosage form in which water is highly blended, and further, the glycyrrhetinic acid derivative It is an object of the present invention to provide a technique for promoting percutaneous absorption of a drug.
　本発明者は、上記目的を達成するため鋭意検討した結果、特定の構成とすることにより、グリチルレチン酸誘導体を含むαゲルが得られ、上記課題を解決できることを知見し、本発明をなすに至ったものである。 The present inventors have conducted intensive studies in order to achieve the above object, and as a result, by adopting a specific configuration, an α-gel containing a glycyrrhetinic acid derivative has been obtained, and it has been found that the above problem can be solved. It is a thing.
　従って、本発明は下記発明を提供する。
１．（Ａ）グリチルレチン酸誘導体、
（Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
（Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上、
（Ｄ）ジプロピレングリコール、及び
（Ｅ）水
を構成成分として有するαゲル。
２．（Ａ）グリチルレチン酸誘導体：０．０５～１質量％、
（Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
（Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上：（Ｂ）成分及び（Ｃ）成分の合計量０．５～２０質量％、
（Ｄ）ジプロピレングリコール２．５～４０質量％、及び
（Ｅ）水
を配合してなり、αゲルを含む組成物。
３．（Ａ）グリチルレチン酸誘導体：０．０５～１質量％、
（Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
（Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上：（Ｂ）成分及び（Ｃ）成分の合計量０．５～２０質量％、
（Ｄ）ジプロピレングリコール２．５～４０質量％、及び
（Ｅ）水
を加熱下で溶解した後に均一に混合し、室温まで冷却する工程を含む、αゲル又はαゲルを含む組成物の製造方法。
４．１記載のαゲルを有効成分として含有する、（Ａ）グリチルレチン酸誘導体の経皮吸収促進剤。
５．１記載のαゲルを含む化粧料。 Therefore, the present invention provides the following inventions.
1. (A) a glycyrrhetinic acid derivative,
(B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
(C) one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants,
Α-gel having (D) dipropylene glycol and (E) water as constituent components.
2. (A) glycyrrhetinic acid derivative: 0.05 to 1% by mass,
(B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
(C) at least one selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: total amount of component (B) and component (C) 0.5 to 20 mass %,
A composition comprising (D) 2.5 to 40% by mass of dipropylene glycol and (E) water and containing an α-gel.
3. (A) glycyrrhetinic acid derivative: 0.05 to 1% by mass,
(B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
(C) at least one selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: total amount of component (B) and component (C) 0.5 to 20 mass %,
Production of α-gel or α-gel-containing composition, comprising the steps of (D) 2.5 to 40% by mass of dipropylene glycol and (E) dissolving water under heating, uniformly mixing and cooling to room temperature. Method.
(A) A transdermal absorption enhancer of a glycyrrhetinic acid derivative, comprising the α-gel of 4.1 as an active ingredient.
A cosmetic comprising the α-gel of 5.1.
　本発明によれば、水が高配合される剤型へのグリチルレチン酸誘導体の配合を可能とし、さらにグリチルレチン酸誘導体の経皮吸収を促進させるαゲルを提供することができる。また、αゲルを含む組成物、αゲルの製造方法、グリチルレチン酸誘導体の経皮吸収促進剤、及びαゲルを含む化粧料を提供することができる。 According to the present invention, it is possible to provide an α-gel capable of blending a glycyrrhetinic acid derivative into a dosage form in which water is highly blended and further promoting percutaneous absorption of the glycyrrhetinic acid derivative. Further, it is possible to provide a composition containing an α-gel, a method for producing the α-gel, a transdermal absorption enhancer of a glycyrrhetinic acid derivative, and a cosmetic containing the α-gel.
実施例１－１、比較例１－１の外観写真を示す。The appearance photographs of Example 1-1 and Comparative Example 1-1 are shown. 実施例１－１のＤＳＣの結果を示す。10 shows the results of DSC of Example 1-1. 実施例１－１のＸ線散乱解析結果を示す。6 shows the results of X-ray scattering analysis of Example 1-1.
　以下、本発明について詳細に説明する。以下、化合物名を化粧品表示名称で記載する場合がある。
[αゲル]
　本発明におけるαゲルとは、（Ａ）グリチルレチン酸誘導体と、（Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上と、（Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上とが、（Ｄ）ジプロピレングリコール、（Ｅ）水との共存下で形成するラメラ状の２分子膜からなる会合体をいう。具体的には、上記（Ｂ）脂肪族アルコール又は脂肪酸のアルキル鎖と、（Ａ）グリチルレチン酸誘導体及び（Ｃ）界面活性剤のアルキル鎖が六方晶を形成している。また、この六方晶構造は二分子膜の積層構造を有しており、α型水和結晶を構造している。α型水和結晶は、その２分子積層構造の層間に大量の水や（Ｄ）ジプロピレングリコールを保持し、２分子膜のネットワーク構造により水分が保持されることでゲル状態の性状を示す。 Hereinafter, the present invention will be described in detail. Hereinafter, the compound name may be described as a cosmetic label.
[α gel]
The α-gel in the present invention includes (A) a glycyrrhetinic acid derivative, (B) one or more selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms, (C) an anionic surfactant, and a cationic interface. An association body comprising a lamellar bimolecular film formed in the presence of (D) dipropylene glycol and (E) water with at least one selected from a surfactant, a nonionic surfactant and an amphoteric surfactant Say. Specifically, (B) the alkyl chain of the aliphatic alcohol or fatty acid, (A) the glycyrrhetinic acid derivative and (C) the alkyl chain of the surfactant form a hexagonal crystal. Further, this hexagonal structure has a laminated structure of a bilayer film, and forms an α-type hydrated crystal. The α-type hydrated crystal retains a large amount of water and (D) dipropylene glycol between the layers of the bilayer structure, and exhibits a gel state by retaining moisture by the network structure of the bimolecular film.
[（Ａ）成分]
　グリチルレチン酸誘導体としては、グリチルレチン酸ステアリル、ステアリン酸グリチルレチニル等が挙げられ、１種単独で又は２種以上を適宜組み合わせて用いることができる。これらはいずれも、親水基と疎水基を有するものである。 [(A) component]
Examples of the glycyrrhetinic acid derivative include stearyl glycyrrhetinate, glycyrrhetinyl stearate, and the like, and these can be used alone or in an appropriate combination of two or more. Each of these has a hydrophilic group and a hydrophobic group.
[（Ｂ）成分]
　本発明の（Ｂ）成分は、炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上であり、１種単独で又は２種以上を適宜組み合わせて用いることができる。これらの脂肪族基は直鎖であることが好ましい。このような特定の成分を選択することで、αゲル構造を構成することができる。
　炭素数１４～１８の脂肪族アルコールとしては、ミリスチルアルコール（１－テトラデカノール）、セチルアルコール（１－ヘキサデカノール）、セトステアリルアルコール、ステアリルアルコール（オクタデシルアルコール）、オレイルアルコール等が挙げられる。中でも、セチルアルコールが好ましい。
　炭素数１４～１８の脂肪酸としては、ミリスチン酸、パルミチン酸、ステアリン酸、オレイン酸等が挙げられる。 [(B) component]
The component (B) of the present invention is at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms, and can be used alone or in an appropriate combination of two or more. These aliphatic groups are preferably straight-chain. By selecting such specific components, an α-gel structure can be formed.
Examples of the aliphatic alcohol having 14 to 18 carbon atoms include myristyl alcohol (1-tetradecanol), cetyl alcohol (1-hexadecanol), cetostearyl alcohol, stearyl alcohol (octadecyl alcohol), and oleyl alcohol. Among them, cetyl alcohol is preferred.
Examples of the fatty acid having 14 to 18 carbon atoms include myristic acid, palmitic acid, stearic acid, and oleic acid.
［（Ｃ）成分］
　本発明の（Ｃ）成分は、アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上であり、１種単独で又は２種以上を適宜組み合わせて用いることができる。 [(C) component]
The component (C) of the present invention is at least one selected from anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants, and one type alone or two or more types as appropriate. They can be used in combination.
　アニオン性界面活性剤は親水基のアルキル鎖がｔｒａｎｓ型のものが好ましく、１種単独で又は２種以上を適宜組み合わせて用いることができる。例えば、アルキルスルホン酸塩、アルキル硫酸塩、アシル化アミノ酸塩、ポリオキシエチレンアルキルエーテル硫酸塩、アルキルベンゼンスルホン酸塩、Ｎ－ステアロイル－Ｎ－メチルタウリン塩等のＮ－アシル－Ｎ－メチルタウリン塩、α－オレフィンスルホン酸塩、高級脂肪酸エステルスルホン酸塩、アルキルエーテル酢酸塩、ポリオキシエチレンアルキルエーテル酢酸塩、ステアリン酸Ｎａ等の脂肪酸石けん、アルキルリン酸エステル塩、Ｎ－ステアロイルグルタミン酸塩、Ｎ－ラウロイルグルタミン酸塩、Ｎ－パルミトイルグルタミン酸塩、Ｎ－ラウロイルグルタミン酸塩、Ｎ－パルミトイルグルタミン酸塩等のアシルグルタミン酸塩、ステアロイル乳酸Ｎａ等のステアロイル乳酸塩、ラウロイル乳酸ナトリウム、Ｎ－ラウロイル－Ｎ－エチルグリシン塩、Ｎ－ラウロイルザルコシン塩、Ｎ－ミリストイル－β－アラニン塩等が挙げられる。塩はアルカリ金属、アルカリ土類金属、アンモニウム、アルカノールアミン、塩基性アミノ酸等が挙げられる。中でも、Ｎ－アシル－Ｎ－メチルタウリン塩、Ｎ－ステアロイルグルタミン酸塩、ステアリン酸塩、ステアロイル乳酸塩等が好ましい。 The anionic surfactant preferably has a trans-type hydrophilic alkyl group, and may be used alone or in combination of two or more. For example, N-acyl-N-methyltaurine salts such as alkyl sulfonates, alkyl sulfates, acylated amino acid salts, polyoxyethylene alkyl ether sulfates, alkylbenzene sulfonates, N-stearoyl-N-methyltaurine salts, α-olefin sulfonate, higher fatty acid ester sulfonate, alkyl ether acetate, polyoxyethylene alkyl ether acetate, fatty acid soap such as sodium stearate, alkyl phosphate ester salt, N-stearoyl glutamate, N-lauroyl Glutamates, N-palmitoyl glutamates, N-lauroyl glutamates, acyl glutamates such as N-palmitoyl glutamate, stearoyl lactates such as sodium stearoyl lactate, sodium lauroyl lactate, N-lauroyl- - ethyl glycine salts, N- lauroyl sarcosine salts, N- myristoyl -β- alanine salts. Salts include alkali metals, alkaline earth metals, ammonium, alkanolamines, basic amino acids and the like. Among them, N-acyl-N-methyltaurate, N-stearoylglutamate, stearate, stearoyl lactate and the like are preferable.
　カチオン性界面活性剤は親水基のアルキル鎖がｔｒａｎｓ型のものが好ましく、１種単独で又は２種以上を適宜組み合わせて用いることができる。具体的には、アルキルトリメチルアンモニウム塩、ジアルキルジメチルアンモニウム塩、アルキルアンモニウム塩等の第四級アンモニウム塩、ベンザルコニウム塩、ピリジニウム塩、アミドアミン化合物等が挙げられる。カチオン性界面活性剤の対イオンとしては、例えば、塩化物イオン、臭化物イオン等のハロゲンイオン、硫酸メチルイオン（ＣＨ3ＯＳＯ3 -）、硫酸エチルイオン（ＣＨ3ＣＨ2ＯＳＯ3 -）等が挙げられる。中でも、トリメチルステアリルアンモニウムクロリド、ヘキサデシルトリメチルアンモニウムクロリド、セチルトリメチルアンモニウムクロリド等が挙げられる。 The cationic surfactant preferably has a trans-type in which the alkyl chain of the hydrophilic group is trans-type, and may be used alone or in combination of two or more. Specific examples include quaternary ammonium salts such as alkyltrimethylammonium salts, dialkyldimethylammonium salts and alkylammonium salts, benzalkonium salts, pyridinium salts, amidoamine compounds and the like. Examples of the counter ion of the cationic surfactant include halogen ions such as chloride ion and bromide ion, methyl sulfate ion (CH 3 OSO 3 − ), and ethyl sulfate ion (CH 3 CH 2 OSO 3 − ). Can be Among them, trimethyl stearyl ammonium chloride, hexadecyl trimethyl ammonium chloride, cetyl trimethyl ammonium chloride and the like can be mentioned.
　ノニオン性界面活性剤としては親水基のアルキル鎖がｔｒａｎｓ型のものが好ましく、１種単独で又は２種以上を適宜組み合わせて用いることができる。具体的には、ポリオキシエチレンセチルエーテル、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンベヘニルエーテル、脂肪酸エステル、グリセリン脂肪酸エステル、モノステアリン酸ポリエチレングリコール、モノステアリン酸ポリオキシエチレングルセリル、脂肪酸ポリオキシエチレンアルキルエーテル、多価アルコール脂肪酸エステル、糖アルコール脂肪酸エステル等が挙げられる。具体的には、モノステアリン酸ポリオキシエチレングリセリル、ポリオキシエチレンステアリルエーテル、モノステアリン酸ポリエチレングリコール、ポリオキシエチレンセチルエーテル等が挙げられる。中でも、ステアリン酸ＰＥＧ－４０グリセリル、αオクタデシルωヒドロキシポリ（オキシエチレン）、ステアリン酸ＰＥＧ－３２、セテス－３０（いずれも化粧品表示名称）が好ましい。 As the nonionic surfactant, those having a trans-alkyl chain of a hydrophilic group are preferable, and one type can be used alone or two or more types can be used in appropriate combination. Specifically, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene lauryl ether, polyoxyethylene behenyl ether, fatty acid ester, glycerin fatty acid ester, polyethylene glycol monostearate, polyoxyethylene glyceryl monostearate And fatty acid polyoxyethylene alkyl ethers, polyhydric alcohol fatty acid esters, sugar alcohol fatty acid esters, and the like. Specific examples include polyoxyethylene glyceryl monostearate, polyoxyethylene stearyl ether, polyethylene glycol monostearate, and polyoxyethylene cetyl ether. Among them, PEG-40 glyceryl stearate, α-octadecyl ω-hydroxypoly (oxyethylene), PEG-32 stearate, and Ceteth-30 (all of which are cosmetic labels) are preferable.
　両性界面活性剤としては親水基のアルキル鎖がｔｒａｎｓ型のものが好ましく、１種単独で又は２種以上を適宜組み合わせて用いることができる。具体的には、アルキルジメチルアミノ酢酸ベタイン等のアルキルベタイン系活性剤、アルキルアミドプロピルベタイン等のアミドベタイン系活性剤、スルホベタイン系活性剤、ヒドロキシスルホベタイン系活性剤、アミドスルホベタイン系活性剤、ホスホベタイン系活性剤、イミダゾリニウムベタイン系活性剤、アミノプロピオン酸系活性剤、アミノ酸系活性剤、アミンオキシド等が挙げられる。中でも、ジメチルオクタデシルアミンＮ－オキシド、ステアリルジメチルアミンオキシド等が好ましい。 As the amphoteric surfactant, those having a trans-alkyl chain of a hydrophilic group are preferable, and one type can be used alone or two or more types can be used in appropriate combination. Specifically, alkyl betaine-based activators such as betaine alkyldimethylaminoacetate, amidobetaine-based activators such as alkylamidopropylbetaine, sulfobetaine-based activators, hydroxysulfobetaine-based activators, amide sulfobetaine-based activators, Examples include phosphobetaine-based activators, imidazolinium betaine-based activators, aminopropionic acid-based activators, amino acid-based activators, and amine oxides. Among them, dimethyloctadecylamine N-oxide, stearyldimethylamine oxide and the like are preferable.
　中でも、アニオン性界面活性剤が好ましく、Ｎ－アシル－Ｎ－メチルタウリン塩、Ｎ－ステアロイルグルタミン酸塩がより好ましい。 Above all, anionic surfactants are preferable, and N-acyl-N-methyltaurate and N-stearoylglutamate are more preferable.
[（Ｄ）成分]
　本発明の（Ｄ）成分はジプロピレングリコールである。ジプロピレングリコールを用いることで、グリチルレチン酸誘導体を含むαゲルを形成させることができる。 [(D) component]
The component (D) of the present invention is dipropylene glycol. By using dipropylene glycol, an α-gel containing a glycyrrhetinic acid derivative can be formed.
[（Ｅ）成分]
　本発明の（Ｅ）成分は水であり、精製水等、水であれば特に限定されない。 [(E) component]
The component (E) of the present invention is water, and is not particularly limited as long as it is water such as purified water.
　αゲルが形成されているかどうかは、αゲルの特徴である、均一の１相状態、好ましくは増粘した均一の１相状態の外観を有し、かつ示差走査熱量分析（ＤＳＣ）から単一の相転移温度を示すことで、αゲルが形成されていることが確認される。さらに、Ｘ線散乱解析によっても確認することができる。 Whether or not an α-gel is formed can be determined by the appearance of a uniform one-phase state, preferably a thickened uniform one-phase state, which is characteristic of the α-gel, and by a single differential scanning calorimetry (DSC). By confirming the phase transition temperature, it is confirmed that an α-gel was formed. Furthermore, it can be confirmed by X-ray scattering analysis.
[αゲルを含む組成物]
　本発明は、（Ａ）グリチルレチン酸誘導体：０．０５～１質量％、
（Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
（Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上：（Ｂ）成分及び（Ｃ）成分の合計量０．５～２０質量％、
（Ｄ）ジプロピレングリコール２．５～４０質量％、及び
（Ｅ）水
を配合してなり、αゲルを含む組成物を提供する。
　この組成物には、上記αゲルが含まれており、αゲル形成の観点から、各成分の含有量は下記の通りとなる。なお、下記含有量には、αゲルを構成するものも含まれる。 [Composition containing α-gel]
The present invention provides (A) a glycyrrhetinic acid derivative: 0.05 to 1% by mass,
(B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
(C) one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: total amount of component (B) and component (C) 0.5 to 20 mass %,
A composition comprising (D) 2.5 to 40% by mass of dipropylene glycol and (E) water and comprising an α-gel is provided.
This composition contains the above-mentioned α-gel. From the viewpoint of α-gel formation, the content of each component is as follows. In addition, what constitutes (alpha) gel is also contained in the following content.
　（Ａ）成分の含有量は、組成物中０．０５～１質量％であり、０．０５～０．５質量％が好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％であり、０．５～１２質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は界面活性剤の種類によって異なるが、０．５：１～５：１が好ましく、１：１～４：１がより好ましく、１．３：１～３：１が最も好ましい。（Ｂ）成分の含有量は、組成物中０．３～１６．０質量％が好ましく、（Ｃ）成分の含有量は、組成物中０．２～８．０質量％が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％であり、２．５～２０質量％が好ましい。 The content of the component (A) is 0.05 to 1% by mass in the composition, and preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is 0.5 to 20% by mass, preferably 0.5 to 12% by mass in the composition. The mass ratio of (B) :( C) varies depending on the type of surfactant, but is preferably 0.5: 1 to 5: 1, more preferably 1: 1 to 4: 1, and 1.3: 1. ３3: 1 is most preferred. The content of the component (B) is preferably 0.3 to 16.0% by mass in the composition, and the content of the component (C) is preferably 0.2 to 8.0% by mass in the composition.
The content of the component (D) is 2.5 to 40% by mass in the composition, and preferably 2.5 to 20% by mass.
　なお、（Ａ）成分：（Ｂ）成分及び（Ｃ）成分の合計：（Ｄ）成分の配合質量比は、０．０５～１：０．５～２０：２．５～４０が好ましい。 The compounding ratio of the component (A): the sum of the components (B) and (C): the component (D) is preferably from 0.05 to 1: 0.5 to 20: 2.5 to 40.
　以下、（Ｃ）成分ごとの、好適な範囲を下記に示す。
　（Ｃ）成分が、Ｎ－アシル－Ｎ－メチルタウリンナトリウムの場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましく、０．５～１２質量％がより好ましい。（Ｂ）：（Ｃ）の質量比は、１：１～５：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～２０質量％がより好ましく、２．５～１０質量％がさらに好ましい。 Hereinafter, suitable ranges for each component (C) are shown below.
When the component (C) is sodium N-acyl-N-methyltaurine,
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably from 0.5 to 20% by mass, more preferably from 0.5 to 12% by mass in the composition. The mass ratio of (B) :( C) is preferably from 1: 1 to 5: 1.
The content of the component (D) in the composition is preferably 2.5 to 40% by mass, more preferably 2.5 to 20% by mass, and still more preferably 2.5 to 10% by mass.
　（Ｃ）成分が、ステアロイルグルタミン酸ナトリウムの場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。（Ｂ）：（Ｃ）の質量比は、１：１～３：１が好ましい。
　（Ｄ）成分の含有量は、組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is sodium stearoyl glutamate,
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. The mass ratio of (B) :( C) is preferably from 1: 1 to 3: 1.
The content of the component (D) is preferably 2.5 to 40% by mass, more preferably 2.5 to 30% by mass in the composition.
　（Ｃ）成分がステアリン酸Ｎａの場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は、１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is sodium stearate,
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｃ）成分がステアロイル乳酸Ｎａの場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は、１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is sodium stearoyl lactate,
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｃ）成分がトリメチルステアリルアンモニウムクロリドの場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は、１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is trimethylstearyl ammonium chloride,
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｃ）成分がヘキサデシルトリメチルアンモニウムクロリド（塩化セチルトリメチルアンモニウム）の場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is hexadecyltrimethylammonium chloride (cetyltrimethylammonium chloride),
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｃ）成分が、ステアリン酸ＰＥＧ－４０グリセリル（モノステアリン酸ポリオキシエチレングリセリル）の場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is PEG-40 glyceryl stearate (polyoxyethylene glyceryl monostearate),
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｃ）成分が、αオクタデシルωヒドロキシポリ（オキシエチレン）（ポリオキシエチレンステアリルエーテル）の場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is α-octadecyl ω-hydroxy poly (oxyethylene) (polyoxyethylene stearyl ether),
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｃ）成分が、ステアリン酸ＰＥＧ－３２（モノステアリン酸ポリエチレングリコール）の場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is PEG-32 stearate (polyethylene glycol monostearate),
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｃ）成分が、セテス－３０（ポリオキシエチレンセチルエーテル）の場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％であり、２．５～３０質量％がより好ましい。 When the component (C) is Cetes-30 (polyoxyethylene cetyl ether),
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is 2.5 to 40% by mass in the composition, and more preferably 2.5 to 30% by mass.
　（Ｃ）成分が、ジメチルオクタデシルアミンＮ－オキシド（ステアリルジメチルアミンオキシド）の場合は、
　（Ａ）成分の含有量は、組成物中０．０５～１質量％が好ましく、０．０５～０．５質量％がより好ましい。
　（Ｂ）成分及び（Ｃ）成分の合計含有量は、組成物中０．５～２０質量％が好ましい。また、（Ｂ）：（Ｃ）の質量比は１：１～６：１が好ましい。
　（Ｄ）成分の含有量は組成物中２．５～４０質量％が好ましく、２．５～３０質量％がより好ましい。 When the component (C) is dimethyloctadecylamine N-oxide (stearyldimethylamine oxide),
The content of the component (A) in the composition is preferably 0.05 to 1% by mass, more preferably 0.05 to 0.5% by mass.
The total content of the components (B) and (C) is preferably 0.5 to 20% by mass in the composition. Further, the mass ratio of (B) :( C) is preferably from 1: 1 to 6: 1.
The content of the component (D) is preferably from 2.5 to 40% by mass, more preferably from 2.5 to 30% by mass in the composition.
　（Ｅ）成分の含有量は、組成物中５８．５～９６．９５質量％が好ましく、７８．５～９６．０質量％がより好ましい。本発明の構成とすることで、このような高含水量の組成物を得ることができる。 The content of the component (E) is preferably 58.5 to 96.95% by mass, more preferably 78.5 to 96.0% by mass in the composition. With the constitution of the present invention, a composition having such a high water content can be obtained.
[任意成分]
　任意成分としては、化粧料、育毛剤、医薬品、医薬部外品等に配合し得る様々な成分を本発明の効果を損なわない範囲で適量配合することができる。このような成分としては、例えば、シリコーン油、エステル油、植物油等の油剤、シリコーン粉体、高分子化合物、エタノール等の溶剤、低級アルコール（炭素数２～５）、高級アルコール（炭素数６～２２）等のアルコール、増粘剤、粉体、美白剤、抗老化剤、保湿剤、防腐剤、抗菌剤、酵素、植物抽出物等の機能性成分の他、香料、色素、ｐＨ調整剤等が挙げられる。これらは、それぞれ１種単独で又は２種以上を適宜組み合わせて用いることができる。 [Optional component]
As the optional component, various components that can be added to cosmetics, hair restorer, pharmaceuticals, quasi-drugs and the like can be added in appropriate amounts as long as the effects of the present invention are not impaired. Examples of such components include oils such as silicone oils, ester oils and vegetable oils, silicone powders, polymer compounds, solvents such as ethanol, lower alcohols (2 to 5 carbon atoms), and higher alcohols (6 to 5 carbon atoms). 22) Functional ingredients such as alcohols, thickeners, powders, whitening agents, anti-aging agents, humectants, preservatives, antibacterial agents, enzymes, plant extracts, etc., as well as fragrances, pigments, pH adjusters, etc. Is mentioned. Each of these can be used alone or in combination of two or more.
［αゲルを含む組成物の物性］
　αゲルを含む組成物の２５℃における粘度は１，０００～１０，０００ｍＰａ・ｓが好ましい。なお、粘度の測定はＢ型粘度計、例えばＢＲＯＯＫＦＩＬＤ社製で測定する。 [Physical Properties of Composition Containing α-Gel]
The viscosity at 25 ° C. of the composition containing the α-gel is preferably from 1,000 to 10,000 mPa · s. The viscosity is measured by a B-type viscometer, for example, manufactured by BROOKFILD.
[αゲル又はαゲルを含む組成物の製造方法]
　αゲル又はαゲルを含む組成物は、
（Ａ）グリチルレチン酸誘導体：０．０５～１質量％、
（Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
（Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上：（Ｂ）成分及び（Ｃ）成分の合計量０．５質量％以上、
（Ｄ）ジプロピレングリコール２．５～４０質量％、及び
（Ｅ）水
を加熱溶解後に均一混合し、室温まで冷却する工程を含むことで、製造することができる。
　加熱温度は特に限定されないが、７０～９０℃が好ましい。混合は特に限定されず、公知の混合装置を用いて混合することができる。混合速度、混合装置、混合時間は特に限定されず、１相増粘物が形成されればよいが、混合速度は１５０ｒｐｍ以上が好ましく、２００ｒｐｍ以上がより好ましい。上限は特に限定されないが、混合装置等により、１０，０００ｒｐｍ以下の範囲で適宜選定することができる。混合時間は１分以上が好ましく、２～１０分がより好ましい。その後、室温（約２０℃）まで冷却する。 [Method for producing α-gel or composition containing α-gel]
α-gel or a composition comprising α-gel,
(A) glycyrrhetinic acid derivative: 0.05 to 1% by mass,
(B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
(C) one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: the total amount of components (B) and (C) is at least 0.5% by mass. ,
It can be manufactured by including a step of uniformly mixing (D) 2.5 to 40% by mass of dipropylene glycol and water (E) after heating and dissolving, and cooling to room temperature.
The heating temperature is not particularly limited, but is preferably from 70 to 90 ° C. Mixing is not particularly limited, and mixing can be performed using a known mixing device. The mixing speed, mixing device, and mixing time are not particularly limited as long as a one-phase thickened substance is formed, but the mixing speed is preferably 150 rpm or more, more preferably 200 rpm or more. The upper limit is not particularly limited, but can be appropriately selected within a range of 10,000 rpm or less by a mixing device or the like. The mixing time is preferably 1 minute or more, more preferably 2 to 10 minutes. Then, it cools to room temperature (about 20 degreeC).
[経皮吸収促進剤]
　本発明のゲル構造体は（Ａ）グリチルレチン酸誘導体の経皮吸収を促進させる優れた効果を有する。このため、このαゲルを有効成分として含有する、（Ａ）グリチルレチン酸誘導体の経皮吸収促進剤を提供する。好適な成分、含有量等は上記の通りである。 [Transdermal absorption enhancer]
The gel structure of the present invention has an excellent effect of promoting percutaneous absorption of the glycyrrhetinic acid derivative (A). Therefore, there is provided (A) a transdermal absorption enhancer of a glycyrrhetinic acid derivative containing the α-gel as an active ingredient. Suitable components and contents are as described above.
[化粧料]
　上記αゲルは化粧料に配合することができ、上記αゲルを含む化粧料を提供することができる。この化粧料は上記αゲルを含む組成物を化粧料としてもよい。さらに、育毛剤、医薬品、医薬部外品等にも配合することができる。αゲルの化粧料中の配合量は、特に限定されず、５～１００質量％の範囲で適宜選択される。 [Cosmetics]
The α-gel can be blended with cosmetics, and a cosmetic containing the α-gel can be provided. This cosmetic may use the composition containing the α-gel as a cosmetic. Furthermore, it can be blended with hair restorers, pharmaceuticals, quasi-drugs, and the like. The amount of the α-gel in the cosmetic is not particularly limited, and is appropriately selected within the range of 5 to 100% by mass.
　化粧料としては特に限定されないが、皮膚化粧料、毛髪化粧料が挙げられる。皮膚化粧料としては、ファンデーション（固形、液状全てを含む）、化粧下地、シャドー、口紅、リップクリーム、チーク、アイブロウ、マスカラ、アイライン、日焼け止め等のメークアップ化粧料、化粧水、乳液、クリーム、美容液、アイクリーム、パック等のスキンケア用化粧料が挙げられる。その他、制汗剤等も挙げられる。毛髪化粧料としては、シャンプー、リンス、トリートメント等が挙げられる。 The cosmetic is not particularly limited, and examples thereof include skin cosmetics and hair cosmetics. Examples of skin cosmetics include foundations (including all solids and liquids), makeup bases, shadows, lipsticks, lip balms, cheeks, eyebrow, mascara, eye lines, sunscreens, and other makeup cosmetics, lotions, emulsions, and creams , Serum, eye cream, pack and the like. Other examples include antiperspirants. Hair cosmetics include shampoos, rinses, treatments and the like.
　以下、実施例及び比較例を示し、本発明を具体的に説明するが、本発明は下記の実施例に制限されるものではない。なお、下記の例において特に明記のない場合は、組成の「％」は質量％、比率は質量比を示し、表中の各成分の量は純分換算した量である。 EXAMPLES Hereinafter, the present invention will be described specifically with reference to Examples and Comparative Examples, but the present invention is not limited to the following Examples. In the following examples, unless otherwise specified, “%” in the composition indicates% by mass, ratio indicates the mass ratio, and the amounts of the respective components in the table are amounts converted to pure components.
　　［実施例、比較例］
　下記組成を９０℃で加熱した後、混合し、振盪機を用いて１０分混合した後、室温（２０℃）まで冷却して組成物を得た。得られた組成物について、下記基準で、組成物の外観及びＤＳＣ測定結果からαゲルの形成を確認した。粘度はＢ型粘度計（ＢＲＯＯＫＦＩＬＤ社製）で測定した。
［αゲルの形成］
○：組成物が増粘した均一の１相状態の外観を有し、ＤＳＣで単一の相転移温度を確認できた。
△：組成物が均一の１相状態の外観を有し、ＤＳＣで単一の相転移温度を確認できた。
×：組成物が２相又は結晶物が確認できた。
△及び○をゲルが形成したとする。 [Examples and Comparative Examples]
The following composition was heated at 90 ° C., mixed, mixed for 10 minutes using a shaker, and then cooled to room temperature (20 ° C.) to obtain a composition. With respect to the obtained composition, formation of an α-gel was confirmed from the appearance of the composition and the result of DSC measurement based on the following criteria. The viscosity was measured with a B-type viscometer (manufactured by BROOKFILD).
[Formation of α-gel]
：: The composition had the appearance of a single-phase state in which the viscosity was increased, and a single phase transition temperature could be confirmed by DSC.
Δ: The composition had a uniform one-phase appearance, and a single phase transition temperature could be confirmed by DSC.
×: The composition was confirmed to have two phases or crystals.
Δ and ○ indicate that a gel was formed.
Figure JPOXMLDOC01-appb-T000001
 　実施例１－１、比較例１－１の外観写真を図１に示す。
　実施例１－１のＤＳＣの結果を図２に示す。
　実施例１－１のＸ線散乱解析結果を図３に示す。
　構造解析からも、αゲルが形成されていることが確認された。
Figure JPOXMLDOC01-appb-T000001
 FIG. 1 shows external appearance photographs of Example 1-1 and Comparative Example 1-1.
FIG. 2 shows the result of DSC of Example 1-1.
FIG. 3 shows the result of X-ray scattering analysis of Example 1-1.
Structural analysis also confirmed that an α-gel was formed.
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000005
Figure JPOXMLDOC01-appb-T000005
Figure JPOXMLDOC01-appb-T000006
Figure JPOXMLDOC01-appb-T000006
Figure JPOXMLDOC01-appb-T000007
Figure JPOXMLDOC01-appb-T000007
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000009
Figure JPOXMLDOC01-appb-T000009
Figure JPOXMLDOC01-appb-T000010
Figure JPOXMLDOC01-appb-T000010
Figure JPOXMLDOC01-appb-T000011
Figure JPOXMLDOC01-appb-T000011
Figure JPOXMLDOC01-appb-T000012
Figure JPOXMLDOC01-appb-T000012
Figure JPOXMLDOC01-appb-T000013
Figure JPOXMLDOC01-appb-T000013
　　［試験例１］
（試料）
（１）ブランク（表１４のジェル組成）：下記組成を混合して調製した。
（２）サンプル（表１５のαゲル組成）：上記実施例と同様の方法で調製した。
○条件（Ｎ＝４）
皮膚モデル：３次元培養表皮モデル（ＥｑｉＳｋｉｎ　ＴＭ－ｌａｒｇｅ　Ｍｏｄｅｌ）
レシーバー液：２０％ＰＥＧ４００／ＰＢＳ（－）：６時間、２４時間後に回収した。
◆透過量（皮膚モデル中への移行量、Ｎ＝４の平均）
　グリチルレチン酸ステアリルの量を高速液体クロマトグラフィー（ＨＰＬＣ）で測定した。
○ＨＰＬＣ測定条件
　カラム：ＹＭＣ－Ｐａｃｋ　Ｐｒｏ　Ｃ１８　（１５０×４．６ｍｍＩ．Ｄ．）
　移動相：メタノール/エタノール　混液（４：１）
　カラム温度：４０℃
　注入量：１０μＬ
　測定波長：２４８ｎｍ
（１）ブランク（ジェル組成）：０．９３０２５μｇ／ｍＬ
（２）サンプル（αゲル組成）：８.０００７５μｇ／ｍＬ [Test Example 1]
(sample)
(1) Blank (gel composition in Table 14): prepared by mixing the following compositions.
(2) Sample (α gel composition in Table 15): Prepared in the same manner as in the above example.
○ Conditions (N = 4)
Skin model: 3D cultured epidermal model (EqiSkin TM-large Model)
Receiver solution: 20% PEG400 / PBS (-): Collected after 6 hours and 24 hours.
◆ Permeation amount (transfer amount into skin model, average of N = 4)
The amount of stearyl glycyrrhetinate was measured by high performance liquid chromatography (HPLC).
○ HPLC measurement conditions Column: YMC-Pack Pro C18 (150 × 4.6 mm ID)
Mobile phase: methanol / ethanol mixture (4: 1)
Column temperature: 40 ° C
Injection volume: 10 μL
Measurement wavelength: 248 nm
(1) Blank (gel composition): 0.93025 μg / mL
(2) Sample (α gel composition): 8.00075 μg / mL
Figure JPOXMLDOC01-appb-T000014
Figure JPOXMLDOC01-appb-T000014
Figure JPOXMLDOC01-appb-T000015
Figure JPOXMLDOC01-appb-T000015
　グリチルレチン酸ステアリルを構成成分として有するαゲルとすることで、グリチルレチン酸ステアリルの経皮吸収が促進された。 Transdermal absorption of stearyl glycyrrhetinate was promoted by using an α-gel having stearyl glycyrrhetinate as a component.

Claims (5)

  1. 　（Ａ）グリチルレチン酸誘導体、
    （Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
    （Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上、
    （Ｄ）ジプロピレングリコール、及び
    （Ｅ）水
    を構成成分として有するαゲル。     (A) a glycyrrhetinic acid derivative,
    (B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
    (C) one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants,
    Α-gel having (D) dipropylene glycol and (E) water as constituent components.
  2. 　（Ａ）グリチルレチン酸誘導体：０．０５～１質量％、
    （Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
    （Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上：（Ｂ）成分及び（Ｃ）成分の合計量０．５～２０質量％、
    （Ｄ）ジプロピレングリコール２．５～４０質量％、及び
    （Ｅ）水
    を配合してなり、αゲルを含む組成物。     (A) glycyrrhetinic acid derivative: 0.05 to 1% by mass,
    (B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
    (C) one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: total amount of component (B) and component (C) 0.5 to 20 mass %,
    A composition comprising (D) 2.5 to 40% by mass of dipropylene glycol and (E) water and containing an α-gel.
  3. 　（Ａ）グリチルレチン酸誘導体：０．０５～１質量％、
    （Ｂ）炭素数１４～１８の脂肪族アルコール及び脂肪酸から選ばれる１種以上、
    （Ｃ）アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤及び両性界面活性剤から選ばれる１種以上：（Ｂ）成分及び（Ｃ）成分の合計量０．５～２０質量％、
    （Ｄ）ジプロピレングリコール２．５～４０質量％、及び
    （Ｅ）水
    を加熱下で溶解した後に均一に混合し、室温まで冷却する工程を含む、αゲル又はαゲルを含む組成物の製造方法。     (A) glycyrrhetinic acid derivative: 0.05 to 1% by mass,
    (B) at least one selected from aliphatic alcohols and fatty acids having 14 to 18 carbon atoms,
    (C) one or more selected from anionic surfactants, cationic surfactants, nonionic surfactants and amphoteric surfactants: total amount of component (B) and component (C) 0.5 to 20 mass %,
    Production of α-gel or α-gel-containing composition, which comprises the steps of (D) 2.5 to 40% by mass of dipropylene glycol and (E) dissolving water under heating, uniformly mixing and cooling to room temperature. Method.
  4. 　請求項１記載のαゲルを有効成分として含有する、（Ａ）グリチルレチン酸誘導体の経皮吸収促進剤。 剤 A transdermal absorption enhancer of a glycyrrhetinic acid derivative, which comprises the α-gel according to claim 1 as an active ingredient.
  5. 　請求項１記載のαゲルを含む化粧料。 化粧 A cosmetic comprising the α-gel according to claim 1.
PCT/JP2019/039037 2018-10-04 2019-10-03 α GEL HAVING GLYCYRRHETINIC ACID DERIVATIVE AS STRUCTURAL COMPONENT, COMPOSITION CONTAINING α GEL, METHOD FOR PRODUCING α GEL, AND COSMETIC CONTAINING α GEL WO2020071464A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020217010922A KR20210071996A (en) 2018-10-04 2019-10-03 α-gel containing glycyrrhetinic acid derivative as a constituent component, composition containing α-gel, method for producing α-gel, and cosmetic containing α-gel
JP2020550525A JPWO2020071464A1 (en) 2018-10-04 2019-10-03 Α-gel containing glycyrrhetinic acid derivative as a constituent, composition containing α-gel, method for producing α-gel, cosmetic containing α-gel
CN201980064673.4A CN112888422A (en) 2018-10-04 2019-10-03 Alpha gel containing glycyrrhetinic acid derivative as constituent, composition containing alpha gel, method for producing alpha gel, and cosmetic containing alpha gel
JP2023195681A JP2024003242A (en) 2018-10-04 2023-11-17 α GEL HAVING GLYCYRRHETINIC ACID DERIVATIVE AS STRUCTURAL COMPONENT, COMPOSITION CONTAINING α GEL, METHOD FOR PRODUCING α GEL, AND COSMETIC CONTAINING α GEL

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018188862 2018-10-04
JP2018-188862 2018-10-04

Publications (1)

Publication Number Publication Date
WO2020071464A1 true WO2020071464A1 (en) 2020-04-09

Family

ID=70054560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/039037 WO2020071464A1 (en) 2018-10-04 2019-10-03 α GEL HAVING GLYCYRRHETINIC ACID DERIVATIVE AS STRUCTURAL COMPONENT, COMPOSITION CONTAINING α GEL, METHOD FOR PRODUCING α GEL, AND COSMETIC CONTAINING α GEL

Country Status (5)

Country Link
JP (2) JPWO2020071464A1 (en)
KR (1) KR20210071996A (en)
CN (1) CN112888422A (en)
TW (1) TW202034895A (en)
WO (1) WO2020071464A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114762656A (en) * 2021-01-12 2022-07-19 伽蓝（集团）股份有限公司 Alpha gel phase, preparation method thereof and bath product containing alpha gel phase
CN115737451A (en) * 2022-11-17 2023-03-07 美出莱(杭州)化妆品有限责任公司 Alpha-gel composition, cosmetic and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115400041B (en) * 2022-06-17 2023-09-29 诺斯贝尔化妆品股份有限公司 Cosmetic composition with alpha gel structure and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045552A (en) * 1996-08-02 1998-02-17 Shiseido Co Ltd Cosmetic
JP2014198670A (en) * 2013-03-13 2014-10-23 株式会社コーセー Dendron negative regulatory agent
WO2016080533A1 (en) * 2014-11-20 2016-05-26 王子ホールディングス株式会社 Percutaneous absorption agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3143983A1 (en) * 2003-02-13 2017-03-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo External dermatological formulation comprising saccharide derivative of alpha, alpha-trehalose
FR2991176B1 (en) * 2012-06-01 2014-12-19 Galderma Res & Dev TOPICAL COMPOSITIONS CONTAINING SOLUBILIZED RETINOID OF HYDROGLYCOLIC GEL TYPE
JP5997546B2 (en) 2012-08-23 2016-09-28 株式会社コーセー Skin external preparation or cosmetic composition in which penetration of active ingredient into skin is promoted

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045552A (en) * 1996-08-02 1998-02-17 Shiseido Co Ltd Cosmetic
JP2014198670A (en) * 2013-03-13 2014-10-23 株式会社コーセー Dendron negative regulatory agent
WO2016080533A1 (en) * 2014-11-20 2016-05-26 王子ホールディングス株式会社 Percutaneous absorption agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114762656A (en) * 2021-01-12 2022-07-19 伽蓝（集团）股份有限公司 Alpha gel phase, preparation method thereof and bath product containing alpha gel phase
CN115737451A (en) * 2022-11-17 2023-03-07 美出莱(杭州)化妆品有限责任公司 Alpha-gel composition, cosmetic and preparation method thereof

Also Published As

Publication number Publication date
CN112888422A (en) 2021-06-01
TW202034895A (en) 2020-10-01
JP2024003242A (en) 2024-01-11
JPWO2020071464A1 (en) 2021-09-02
KR20210071996A (en) 2021-06-16

Similar Documents

Publication Publication Date Title
JP4040527B2 (en) Lipid composition and external preparation for skin containing the same
WO2020071464A1 (en) α GEL HAVING GLYCYRRHETINIC ACID DERIVATIVE AS STRUCTURAL COMPONENT, COMPOSITION CONTAINING α GEL, METHOD FOR PRODUCING α GEL, AND COSMETIC CONTAINING α GEL
JP2017025062A (en) TOPICAL DELIVERY OF SKIN COMPOSITIONS HAVING LOW pH
BRPI0813092B1 (en) oil-in-water emulsion composition and method for producing it.
JP2003176211A (en) Oily thickened gel-like composition, emulsified composition using the same and method for preparing the emulsified composition
JP5755517B2 (en) Oily gel cleansing composition
JP2002338459A (en) Method for solubilizing ceramide and ceramide- formulated skin care preparation obtained by using the method
JP5214872B2 (en) Vesicle composition and external preparation for skin containing the same
JP2008195665A (en) Oily gel-shaped composition
JP2007186498A (en) Oily gel-like composition
JP7063265B2 (en) Creamy composition
JP2006225373A (en) Emulsion
EP3738576A1 (en) Gel-state composition and production method therefor
JP6852261B2 (en) Multilamella vesicle preparation containing acyl basic amino acid derivative and bioactive substance
JPWO2015064681A1 (en) Composition for external use
WO2014168193A1 (en) Composition for external use
JPWO2017209182A1 (en) Oily gel composition and cosmetic or skin external preparation containing the same
JP2014012653A (en) Oil for cosmetic, and cosmetic blending the same
JP2017214323A (en) Stable composition for skin quality ameliorating agent
JP5824323B2 (en) Water-in-oil emulsion composition
JP2019099580A (en) Oily gel-like composition and cosmetic and skin external preparation containing the same
JP3600434B2 (en) Transparent oil composition
JP3556479B2 (en) Skin pre-treatment agent
JP2000229811A (en) Skin lotion
KR19990023233A (en) Cosmetic composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19869365

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020550525

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19869365

Country of ref document: EP

Kind code of ref document: A1